235 related articles for article (PubMed ID: 35181378)
21. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
22. MDM2 and CDK4 amplifications are rare events in salivary duct carcinomas.
Grünewald I; Trautmann M; Busch A; Bauer L; Huss S; Schweinshaupt P; Vollbrecht C; Odenthal M; Quaas A; Büttner R; Meyer MF; Beutner D; Hüttenbrink KB; Wardelmann E; Stenner M; Hartmann W
Oncotarget; 2016 Nov; 7(46):75261-75272. PubMed ID: 27662657
[TBL] [Abstract][Full Text] [Related]
23. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
24. Amplification of Mdmx and overexpression of MDM2 contribute to mammary carcinogenesis by substituting for p53 mutations.
Yu Q; Li Y; Mu K; Li Z; Meng Q; Wu X; Wang Y; Li L
Diagn Pathol; 2014 Mar; 9():71. PubMed ID: 24667108
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
26. Oncogene and therapeutic target analyses in atypical fibroxanthomas and pleomorphic dermal sarcomas.
Helbig D; Ihle MA; Pütz K; Tantcheva-Poor I; Mauch C; Büttner R; Quaas A
Oncotarget; 2016 Apr; 7(16):21763-74. PubMed ID: 26943575
[TBL] [Abstract][Full Text] [Related]
27. Primary cardiac sarcomas: A clinicopathologic study in a single institution with 25 years of experience with an emphasis on MDM2 expression and adjuvant therapy for prognosis.
Cho H; Song IH; Jo U; Jeong JS; Koo HJ; Yang DH; Jung SH; Song JS; Cho KJ
Cancer Med; 2023 Aug; 12(16):16815-16828. PubMed ID: 37395142
[TBL] [Abstract][Full Text] [Related]
28. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
29. The
Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
[TBL] [Abstract][Full Text] [Related]
30. Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas.
Cordon-Cardo C; Latres E; Drobnjak M; Oliva MR; Pollack D; Woodruff JM; Marechal V; Chen J; Brennan MF; Levine AJ
Cancer Res; 1994 Feb; 54(3):794-9. PubMed ID: 8306343
[TBL] [Abstract][Full Text] [Related]
31. Undifferentiated pleomorphic sarcoma with co-existence of KRAS/PIK3CA mutations.
Li B; Li L; Li X; Wang Y; Xie Y; Liu C; Li F
Int J Clin Exp Pathol; 2015; 8(7):8563-7. PubMed ID: 26339434
[TBL] [Abstract][Full Text] [Related]
32. Automated brightfield dual-color in situ hybridization for detection of mouse double minute 2 gene amplification in sarcomas.
Zhang W; McElhinny A; Nielsen A; Wang M; Miller M; Singh S; Rueger R; Rubin BP; Wang Z; Tubbs RR; Nagle RB; Roche P; Wu P; Pestic-Dragovich L
Appl Immunohistochem Mol Morphol; 2011 Jan; 19(1):54-61. PubMed ID: 20881839
[TBL] [Abstract][Full Text] [Related]
33. Cardiac intimal sarcoma with PDGFRβ mutation and co-amplification of PDGFRα and MDM2: an autopsy case analyzed by whole-exome sequencing.
Ito Y; Maeda D; Yoshida M; Yoshida A; Kudo-Asabe Y; Nanjyo H; Izumi C; Yamamoto F; Inoue M; Shibata H; Katoh H; Ishikawa S; Nakamura H; Totoki Y; Shibata T; Yachida S; Goto A
Virchows Arch; 2017 Sep; 471(3):423-428. PubMed ID: 28474091
[No Abstract] [Full Text] [Related]
34. Rb and p53-Deficient Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma Require Skp2 for Survival.
Li GZ; Okada T; Kim YM; Agaram NP; Sanchez-Vega F; Shen Y; Tsubokawa N; Rios J; Martin AS; Dickson MA; Qin LX; Socci ND; Singer S
Cancer Res; 2020 Jun; 80(12):2461-2471. PubMed ID: 32161142
[TBL] [Abstract][Full Text] [Related]
35. Deregulation of the p14ARF/Mdm2/p53 pathway and G1/S transition in two glioblastoma sets.
Ghimenti C; Fiano V; Chiadò-Piat L; Chiò A; Cavalla P; Schiffer D
J Neurooncol; 2003 Jan; 61(2):95-102. PubMed ID: 12622447
[TBL] [Abstract][Full Text] [Related]
36. Deregulation of the p14ARF/MDM2/p53 pathway is a prerequisite for human astrocytic gliomas with G1-S transition control gene abnormalities.
Ichimura K; Bolin MB; Goike HM; Schmidt EE; Moshref A; Collins VP
Cancer Res; 2000 Jan; 60(2):417-24. PubMed ID: 10667596
[TBL] [Abstract][Full Text] [Related]
37. [Molecular biology of soft-tissue sarcomas].
Coindre JM
Bull Cancer; 2010 Nov; 97(11):1337-45. PubMed ID: 21084242
[TBL] [Abstract][Full Text] [Related]
38. Overlapping features between dedifferentiated liposarcoma and undifferentiated high-grade pleomorphic sarcoma.
Chung L; Lau SK; Jiang Z; Loera S; Bedel V; Ji J; Weiss LM; Chu PG
Am J Surg Pathol; 2009 Nov; 33(11):1594-600. PubMed ID: 19574885
[TBL] [Abstract][Full Text] [Related]
39. Numerical and structural chromosomal anomalies in undifferentiated pleomorphic sarcoma.
Becerikli M; Wieczorek S; Stricker I; Nambiar S; Rittig A; Epplen JT; Tannapfel A; Lehnhardt M; Steinstraesser L; Jacobsen F
Anticancer Res; 2014 Dec; 34(12):7119-27. PubMed ID: 25503139
[TBL] [Abstract][Full Text] [Related]
40. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]